The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

Incretin-based therapies, the most recent therapeutic options for type 2 diabetes mellitus (T2DM) management, can modify various elements of the disease, including hypersecretion of glucagon, abnormal gastric emptying, postprandial hyperglycaemia, and, possibly, pancreatic β cell dysfunction. Dipept...

Descripción completa

Detalles Bibliográficos
Autores principales: Godinho, Ricardo, Mega, Cristina, Teixeira-de-Lemos, Edite, Carvalho, Eugénia, Teixeira, Frederico, Fernandes, Rosa, Reis, Flávio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449938/
https://www.ncbi.nlm.nih.gov/pubmed/26075286
http://dx.doi.org/10.1155/2015/806979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449938/
https://www.ncbi.nlm.nih.gov/pubmed/26075286
http://dx.doi.org/10.1155/2015/806979

Ejemplares similares